Products with Anti-bone loss bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2186 | Vitamin D3 |
| Vitamin D3 is a form of vitamin D, binds and activates a H305F/H397Y mutant vitamin D receptor (VDR) with EC50 of 300 nM. Supplemental calcium and Vitamin D3 may increase TGFβ1 expression and shift TGFα expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients. | |
| BCN2208 | Ergocalciferol |
| Ergocalciferol (Vitamin D2) is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 mM. Ergocalciferol can delay the development of secondary hyperparathyroidism in children with CKD2-3. Ergocalciferol can cause HL-60 apoptosis via a modulation of mitochondria involving ROS production, GSH depletion, caspase activation, and Fas induction, on the basis of anticancer activity of ergocalciferol, it may be feasible to develop chemopreventive agents from edible mushrooms or hop. Ergocalciferol can prevent glucocorticoid-induced bone loss, but even increase lumbar spine and femoral neck bone mineral densities (BMD) in postmenopausal women commencing glucocorticoid therapy, it also is safe and effective in reducing the risk of a fracture in elderly patients with AD. | |
| BCN2209 | Vitamin K1 |
| Vitamin K1, a fat-soluble, naturally occurring vitamin required for blood coagulation and bone and vascular metabolism. Vitamin K1 has anticoagulation activity, it may attenuate liver fibrosis by inhibiting hepatic stellate cell activation in bile duct-ligated rats; it inhibits diabetic-cataract by modulating lens Ca2+ homeostasis and its hypoglycemic effect through its direct action on the pancreas.Vitamin K1 may substantially contribute to reducing postmenopausal bone loss at the site of the femoral neck. | |
| BCN2285 | Sagittatoside A |
| Sagittatoside A selectively activates estrogen response element (ERE)-luciferase activity via ERα, and sagittatoside A and icariin induces ERα phosphorylation at serine 118 residue. | |
| BCN2294 | Sophoricoside |
| Sophoricoside has anti-inflammatory, anti-cancer, anti-bone loss, and immunosuppressive effects. Sophoricoside is an effective regulator of lipogenesis and glucose consumption and may find utility in the treatment of obesity and type 2 diabetes. Sophoricoside exposure reduced the number of implanted embryos in a dose-dependent manner and failed the embryo implantation through altering the morphology of uterine and compromising the endometrial receptivity. | |
